Skip to main content
. Author manuscript; available in PMC: 2015 Feb 5.
Published in final edited form as: Breast Cancer Res Treat. 2014 Feb 22;144(2):287–298. doi: 10.1007/s10549-014-2877-y

Fig. 1.

Fig. 1

MLN0128 and TSA inhibit the proliferation of breast cancer cells more than non-transformed mammary epithelial cells. Viability assays were carried out after 72 h of treatment with the indicated doses of MLN0128 and TSA on the following cell lines: a SKBR3, b MDA-MB-231, c MCF7, d MCF7/HER2-18, e BT-474, and f MCF-10A. Error bars represent the standard deviation calculated from three triplicate wells. Each cell line was analyzed at least twice, and a representative experiment is shown